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ABSTRACT 
Objective: The present study was undertaken to investigate the bioavailability enhancing effect of the natural bioavailability enhancers, piperine 
and ginger oleoresin on the antiretroviral drug atazanvir in combination with ritonavir.  
Methods: Sprague-Dawley rats of either sex, were used for the bioavailability studies of ATV and RTV in combination of Piperine. All the drugs were 
administered orally in the form of suspension to the animals. The bioavailability studies were performed by determination of the drugs 
concentration in plasma by the HPLC. 
Results: The bioavailability of atazanvir was found to be significantly increased in combination with piperine and ginger oleoresin. However, 
piperine has demonstrated better effect as compared to ginger oleoresin in all the groups. Piperine (30 mg/kg) when administered in combination 
with atazanvir (ATV), has shown to increase the bioavailibility of both the doses of ATV (6.5 mg/250 gm) and ATV (3.25 mg/250 gm) significantly 
as compared to the conventional doses.  
Conclusion: Results of the investigation proves a significant bioavailability enhancement effect of piperine and ginger oleo resin on atazanavir in 
lower doses as well as in the absence of rotinavir. These studies places piperine as a mode of increasing activity of atazanvir.  
Keywords: Atazanvir, Ritonavir, Bioavailabilty enhancers, Piperine, Ginger oleoresin.  
 
INTRODUCTION 
HIV-protease inhibitors play a very important role in antiretroviral 
drug therapy for the treatment of HIV-AIDS. The aspartic protease of 
human immunodeficiency virus is responsible for the cleavage of the 
viral Gag and Gag-Pol polyprotein precursors into mature, functional 
viral enzymes and structural proteins. This process, called viral 
maturation, which leads to the final morphological rearrangements, 
is indispensable for production of infectious viral particles [1]. If 
HIV-PR is inhibited, the nascent virions cannot go on to attack other 
cells and the spreading of HIV is therefore stopped. 
The agents in this category inhibit HIV aspartic protease which is 
essential for post-translational proteolysis of gag and gag-pol 
polyproteins. Inhibition of that proteolysis results in the release of 
immature HIV that is no longer infectious [2, 3]. The protease 
inhibitors, compared to nucleoside analogues, undergo a very different 
metabolism in humans. In general, similar to non-nucleoside reverse 
transcriptase inhibitors, protease inhibitors are substrates for 
cytochrome P450 oxidation. Thus, a number of clinically relevant 
drug–drug interactions have been documented with regard to the 
metabolism of these agents. Oral bioavailability of these agents is poor 
[4]. They are competitive inhibitors of HIV PR and all but one are 
peptidomimetics of the polyprotein cleavage sites.  
Currently available anti-HIV protease inhibitors have relatively 
short half-life, low bioavailability, poor CNS penetration and 
retention, and undesirable side effects. These drawbacks give us 
opportunities to design and develop novel drug delivery systems to 
overcome transport barriers and inherent elimination/metabolism 
problems associated with these anti-HIV drugs. The delivery 
systems of these anti-HIV drugs have been developed to compensate 
the short half-life, circulation time, increase bioavailability, improve 
CNS penetration and retention, and deliver the drugs to target 
cells/tissues [5]. Many of these protease inhibitors have been 
studied for their bioavailability enhancing activity with piperine. As 
such studies have not been performed using Atazanvir, its detailed 
bio-enhancing activity has been studied in this paper in combination 
with piperine and ginger oleoresin. 
Atazanavir 
Atazanavir (ATV) methyl N-[(2S)-1-[2-[(2S,3S)-2-hydroxy-3-[[(2S)-2-
(methoxycarbonylamino)-3,3 dimethyl- butanoyl]amino]-4-phenyl 
butyl]-2-[(4-pyridin-2-ylphenyl)methyl]hydrazinyl]-3,3-di methyl-1-
oxobutan-2-yl]carbamate with molecular formula C38H52N6O7 and 
molecular weight 704.8 is an antiretroviral drug of the protease 
inhibitor (PI) class. Like other antiretrovirals, it is used to treat 
infection of human immunodeficiency virus (HIV) and is used in 
combination with other HIV medications. It is the first protease 
inhibitor approved for once-daily dosing, and also appears to be less 
likely to cause lipodystrophy and elevated cholesterol as side effects. It 
may also not be cross-resistant with other protease inhibitor. The U. S. 
The food and Drug Administration (FDA) approved atazanavir with 
three different strengths such as 100 mg, 150 mg and 200 mg, on June 
20, 2003. On October 20, 2006, the FDA approved a new formulation 
of ATV (300 mg capsules) to be taken as part of combination drug 
therapy [6]. This formulation should reduce pill burden, as one 300 mg 
capsule may replace two 150 mg capsules.  
Dose of Atazanavir alone-400 mg orally once a day (OD) while 
Atazanavir+Ritonavir-300 mg orally OD+100 mg orally OD. 
Cytochome P (CYP) enzyme CYP3A4 is the major isoenzyme responsible 
for ATV metabolism. ATV is a competitive inhibitor of CYP3A4 
(Inhibition rate constant (Ki) = 2.35 μM) and UGT1A1 (Ki = 1.9 μM) at 
clinically relevant concentrations. ATV also competitively inhibits 
CYP1A2 and CYP2C9, but the Ki values (Ki ≥ 12.2 μM) were higher than 
steady-state plasma concentrations, suggesting that ATV is unlikely to 
inhibit CYP1A2 and CYP2C9 substrates at the recommended dose [7, 8]. 
The most common side effects of ATV include diarrhea, nausea or 
vomiting, headache, and fatigue. Others include circumoral 
paresthesia (tingling sensation around the mouth), and changes in 
liver function, which can be detected and monitored with laboratory 
tests. An increase in bilirubin (by product of red blood cell break 
down) has been associated with ATV. Sometimes the increase in 
bilirubin results in jaundice (yellowing of skin and eyes). ATV has 
demonstrated a low incidence of lipodystrophy [9, 10]. 
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Ritonavir (RTV) 1,3-thiazol-5-ylmethyl N-[(2S,3S,5S)-3-hydroxy-5-[(2S)-
3-methyl-2-{[methyl({[2-(propan-2-yl)-1,3-thiazol-4-yl] methyl}) 
carbamoyl] amino} butanamido]-1,6-diphenyl-hexan-2-yl] 
carbamate with molecular formula C37H48N6O5S2
It undergoes rapid first-pass metabolism in the liver by CYP3A4 and 
CYP3A5. It inhibits the CYP3A4 isoenzyme in the human liver 
microsomes and results in drug interaction [11]. 
 and molecular 
weight 720.9. Ritonavir is the first and only co-formulated HIV-1 
protease inhibitor (PI). Large clinical trials have demonstrated RTV’s 
clinical efficacy in both antiretroviral-naive and experienced 
patients. The immunologic and virologic benefits of treatment with 
this agent have been proven in HIV-infected adults, adolescents, and 
children. Smaller studies support the use of RTV monotherapy as a 
therapeutic option in certain patients. The drug is characterized by a 
high genetic barrier to resistance, and appears to be more forgiving 
of non-adherence than earlier, unboosted PIs. RTV is frequently 
prescribed with highly active antiretroviral therapy (HAART), not 
for its antiviral action, but as it inhibits the same host enzyme that 
metabolizes other protease inhibitors. This inhibition leads to higher 
plasma concentrations of these latter drugs, allowing the clinician to 
lower their dose and frequency and improving their clinical efficacy. 
The Dose of RTV alone is 300 mg orally twice a day while RTV in 













The most frequent side effects of ritonavir includes diarrhea, nausea, 
and vomiting. These gastrointestinal adverse effects are generally mild 
to moderate. Immune reconstitution syndrome has been reported in 
patients treated with antiretroviral regimens containing RTV, 
manifested as an inflammatory response to indolent opportunistic 
infections [12, 13]. The above data reveals that the adverse effects of 
both ATV and RTV are higher and it can be reduced by lowering the 
doses of the drugs. But if we reduce the dose of the drugs, then it is 
also necessary that the same plasma concentration should be achieved 
to have the same therapeutic effects. This problem can be resolved if 
we use the bioenhancer with the lower dose of the drug. 
Bioavailability enhancers 
Piperine, an amide alkaloid obtained from the mature fruits of Piper 
nigrum and P. longum, is the first and till date the most potent 
bioenhancer to be discovered. The bioenhancing activity of piperine 
and the concept of bioavailability enhancement using piperine both 
were discovered and scientifically validated in 1979 in India [14]. It 
was studied successfully to reduce the dose of the drug and cost of 
the treatment. Collaborative studies conducted by Cadila Labs Ltd. at 
Regional Research Laboratory, Jammu, led to successful launching of 
the well known antitubercular drug Rifampin (200 mg) along with 
bioenhancer piperine (10 mg) under the trade name ‘Risorine’, in 
2009. In the above case, Rifampicin’s conventional dose of 450 mg 
has been reduced to 200 mg with the same bioavailability [15].  
Piperine brings about its bioenhancing activity by inhibition of P-
glycoprotein drug efflux pump (PGP2) and by inhibiting cytochome 






All the drugs metabolized by these enzymes are influenced by 
bioenhancer piperine [16]. All categories of drugs like cardiovascular, 
respiratory, anticancer, immunomodulatory drugs, drugs acting on the 
central nervous system and gastrointestinal tract, antibiotics and 
several other classes of drugs and nutraceuticals are greatly influenced 
by piperine. It is interesting to note that piperine brings about its 
bioenhancing effect in a dose of 10 mg in all formulations irrespective 
of the dose of combination drug. 
 
Ginger oleo-resin 
The drug consist of oleo-resin isolated from the rhizome of the plant 
Zingiber officinalis Roscoe, family Zingiberaceae, commonly known as 
ginger. Many drugs are found to be more active when used in 
combination with bio enhancer products developed from oleo-resin of 
ginger. The effective range for ginger oleo-resin as a bioenhancer is 10-
150 mg. Class of drugs which has shown enhanced activity are drugs 
acting on the cardiovascular and central nervous system, anti 
retrovirals, anti-inflammatory, antiarthitic, antitubercular, antileprotic, 
anti ulcer and many other therapeutic agents [17, 18].  
MATERIALS AND METHODS 
Plant material, chemicals and reagents 
All crude drugs namely Black pepper, Piper nigrum and Ginger, 
Zingiber officinalis, was procured from reliable sources. Fenugreek 
seeds, Black pepper and Ginger rhizomes were procured from local 
market of Bilaspur. The drug samples of atazanavir and ritonavir 
used in the present study were procured as the gift sample from 
Cipla Laboratories, Mumbai. 
Isolation of Piperine: Dried ripe fruits of black pepper, Piper nigrum 
were defatted with petroleum ether (60-80 °) in soxhlet extractor 
for 24 h. The extract was dried and further extracted with ethyl 
alcohol (95%) for 48 h. The total ethyl alcohol extract was cooled 
and filtered to remove fine particles if necessary, and concentrated 
under reduced pressure to yield total alcohol extract in 2.5% yield. 
The concentrated solution was kept in an ice bath, and water was 
added drop wise (about 30 ml will be required) to precipitate 
piperine. Piperine was collected on a sintered glass funnel. It was 
further recrystallized from acetone: hexanes (3:2) to afford pale 
yellow crystals of piperine (7%). Thin layer chromatographic study 
of isolated piperine along with the authentic primary standard has 
shown a single spot of Rf
Isolation of Ginger Oleo Resin (GOR): About 250g of completely 
dried ginger was powdered in a mechanical grinder, finely shifted 
and subjected to continuous hot percolation process using soxhlet 
apparatus, by using solvents petroleum ether and then with ethanol 
for 24 and 48 h respectively. The extracts thus obtained were 
concentrated to a thick brownish yellow semi-solid mass using Rotary 
vacuum evaporator or water bath. The thick pasty mass was added to 
water to precipitate oleo-resin. The practical yield was found to be 2.9 
%. The oleo-resin extract was subjected to thin layer chromatography 
using silica gel G and petroleum ether: ethyl acetate (7:3) as a solvent 
system. The Rf values of the oleo-resin constituents were found as per 
the reported values in the literature [19]. 
 0.52, in solvent system toluene-ethyl 
acetate (7:3) when spread with Dragendorff’s reagent [14, 15]. 
Bioavailability studies 
Animals 
Sprague-Dawley rats of either sex, weighing 200±50 gm, of almost 
same age, were used for the bioavailability studies of ATV and RTV 
in combination of Piperine. The animals were provided with food 
and water before and during the study protocol. Ethical approval 
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was obtained from the Committee for the purpose of control and 
supervision of experimental animals (CPCSEA), Chennai, India. The 
study was performed as per the standard operating procedures for 
Institutional animal ethics committee of the CPCSEA. In each group, 
three animals were used the blood was collected five times. The 
weight of the rats was recorded in each group on the day of the 
study, before the commencement of the study. 
The dose of the drugs-ATV (H-6.5 mg/250 gm), ATV (L-3.25 mg/250 
gm) and RTV (2.13 mg/250 gm) and the dose of the bioenhancers-
piperine (30 mg/kg) and gingerol (30 mg/kg), was calculated 
according to the body weight of the rats. For the doses given in 
above brackets, ‘H’ and ‘L’ stands for ‘Higher’ and ‘Lower’, 
respectively.  
For the control group, saline was administered first and then the 
drug after an interval of 30 min. For the treated group, bioenhancers 
were administered first and then the drug after an interval of 30 
min. The drug and bioenhancer samples for oral administration to 
the animals were prepared in 2% tragacanth solution. 
The drug bioavailability studies were done by determinations of the 
drugs concentration in plasma by the High performance liquid 
chomatography (HPLC). The solvents required for the HPLC studies 
are Acetonitrile, Ammonium formate and water [20-22].  
Sigma-Aldrich-Ammonium formate buffer of pH=3, 10 mM was 
required for the HPLC studies. Ammonium formate, 0.63 gm, was 
weighed and dissolved in 900 ml of HPLC grade water. The pH of the 
solution was maintained to 3 with orthophosphoric acid, where 
orthophosphoric acid was diluted with water in the ratio of 1:5. 
When the pH of the solution was maintained, then the volume of the 
buffer was made to 1000 ml. The acetonitrile and ammonium 
formate buffer was mixed in the ratio of 45:55 v/v. This solution was 
used as the mobile phase for the HPLC of the drugs, ATV and RTV.  
HPLC studies 
The HPLC was used for the detection of the retention time, peak area 
and concentration of the drugs. HPLC maker & model: Shimadzu 
2010 CHT with a column of 250 mm X 4.6 mm X 5 micron 
(Princeton) was used for the present study.  
After 30 min of drug administration, the blood was withdrawn from 
the rats. Prior to blood withdrawal, the rats were anaesthetized with 
ketamine, at a dose of 0.6 ml/kg. Then the blood was collected at 
regular intervals and 5 samples were withdrawn from each group. The 
blood was withdrawn as follows after every 30 min, 1, 3, and 6 h.  
The blood was kept in the refrigerator, till its centrifugation. The 
plasma separation was done in the cooling centrifuge. The blood was 
centrifuged at 2000-3000 rpm for 20 min. After the separation, the 
plasma samples were stored at-20˚C, till the HPLC studies [22]. 
For HPLC studies, the plasma samples were centrifuged again, with 
the addition of the mobile phase. The supernatant liquid obtained 
after the centrifugation of the samples was injected into the column. 
The method followed for centrifugation is as follows:  
2M sodium carbonate (400 µl), n-hexane: ethyl acetate (50:50) 
(800 µl) and vortex the plasma sample carefully Plasma samples 
and centrifuge the samples at 10,000 rpm, at temperature-10 to-
20˚C. Two layers were obtained, the upper organic layer and 
lower aqueous layer. The organic layer was separated for further 
process and the aqueous layer was discarded. The organic layer 
was left for overnight for complete evaporation of the solvent. 
To the residue, mobile phase was added and centrifuged the 
samples at 10,000 rpm, at temperature-10 to-20˚C. The 
supernatant liquid obtained was carefully collected and 
subjected to HPLC studies. The drug ATV, with the help of UV set 
at 210 nm.  
Besides the plasma samples, the HPLC of ATV-8 µg/ml, was also 
done. This served to be the standard with the peak area and 
retention time of 166732 and 12.469 respectively. This peak area 
was considered to be 100 %. The concentration of the samples was 
determined from peak area of the respective samples with the help 
of data of the standard sample. 
HPLC analysis 
The plasma samples were analyzed with HPLC for the drug ATV, 
with the help of UV set at 210 nm. After the extracts were obtained, 
the animal studies were done. The animals were divided in ten 
groups where each group contained two animals. The control groups 
were treated with saline and drug, and treated groups with piperine 
and GOR along with the drug. The rats were pre treated with saline 
in case of control and with piperine and GOR in case of treated. The 
blood samples were withdrawn from the rats. From 0.30 to 2 hour, 
thee samples were withdrawn from one rat and from 2 to 6 h, two 
samples were withdrawn from other rat of the same group in the 
anticoagulant added tubes. After collection of blood samples, they 
were centrifuged and plasma was collected. This plasma before 
injecting into the column of the HPLC was centrifuged with the 
mobile phase again. The resulting supernatant liquid so obtained 
was then injected into the column. The plasma samples were then 
analyzed for the drug ATV. Besides the plasma samples, the HPLC of 
ATV-8 µg/ml, was also done. This served to be the standard with the 
peak area and retention time of 166732 and 12.469 respectively. 
This peak area was considered to be 100 %. The concentration of the 
samples was determined from peak area of the respective samples 
with the help of data of the standard sample. 
Statistical analysis 
The results were presented as the means S. E. M. One way analysis of 
variance (ANOVA) followed by Dunnett’s test for multiple 
comparisons. 
RESULTS AND DISCUSSION 
ATV and RTV were subjected to bioavailability studies in the 
presence of natural bioavailability enhancer’s piperine and GOR. For 
ATV group, higher dose (6.5 mg/250 gm), ATV (H) and lower dose 
(3.25 mg/250 gm) ATV (L) were selected to examine the 
bioavailability of both the conventional doses in combination with 
RTV (2.13 mg/250 gm), piperine and GOR. The results of the studies 
have been given in table 1,2 and fig. 1,2. 
 
 
Fig. 1: The concentration of ATV (6.5 mg/250 gm) in all the 
plasma samples as analyzed by the HPLC 
 
 
Fig. 2: The concentration of ATV (3.25 mg/250 gm) in all the 
plasma samples as analyzed by the HPLC 
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Table 1: Mean retention time, peak area and plasma concentration of ATV (6.5 mg/250 gm) in all the plasma samples as analyzed by the HPLC 
Sample Time Mean retention time (Average) Mean peak area Mean Plasma conc. (µg/ml) 
Control 
Saline+ 
ATV(6.5 mg/250 gm) 
30 min 12.348 103143 4.90 
1 h 12.426 31733 1.52 
2 h 12.386 110584 5.30 
3 h 12.411 128194 6.15 
6 h 12.317 94639 4.54 
Control 
Saline+ 
ATV(6.5 mg/250 gm)+ 
RTV (2.13 mg/250 gm) 
30 min 11.111 78575 3.77 
1 h 11.178 218016 10.48 
2 h 11.127 225026 10.82 
3 h 11.133 132572 6.37 
6 h 11.150 71839 3.45 
ATV(6.5 mg/250 gm)+ 
Piperine (30 mg/kg)  
30 min 12.287 99370 4.76 
1 h 12.373 190849 9.16 
2 h 12.456 177023 8.49 
3 h 12.377 40566 1.94 
6 h 12.384 63344 3.04 
ATV (6.5 mg/250 gm)+ 
RTV (2.13 mg/250 gm)+Piperine (30 mg/kg) 
30 min 11.072 34809 1.67 
1 h 11.110 33158 1.59 
2 h 11.099 25771 1.24 
3 h 11.185 120059 5.77 
6 h No readings as animal died 
ATV(6.5 mg/250 gm)+ 
GOR (30 mg/kg)  
30 min 12.401 145840 7.0 
1 h 12.267 83584 4.01 
2 h 12.256 104696 5.02 
3 h 12.321 29655 1.42 
6 h 12.268 18406 0.88 
 
Table 2: Mean retention time, peak area and plasma concentration of ATV (3.25 mg/250 gm) in all the plasma samples as analyzed by the HPLC 
Sample Time Mean retention time (Average) Mean peak 
area 
Mean plasma conc. (µg/ml) 
Control 
Saline+ 
ATV (3.25 mg/250 gm) 
30 min 12.574 66834 3.20 
1 h 12.445 51404 2.46 
2 h 12.512 41023 1.96 
3 h 12.246 90882 4.36 
6 h 12.401 76684 3.68 
Control 
Saline+ 
ATV (3.25 mg/250 gm)+ 
RTV (2.13 mg/250 gm) 
30 min 11.176 148392 7.14 
1 h 11.059 63867 3.07 
2 h 11.236 126701 6.09 
3 h 11.106 114630 5.51 
6 h 11.029 31509 1.515 
ATV(3.25 mg/250 gm)+ 
Piperine (30 mg/kg)  
30 min 12.427 60832 2.91 
1 h 12.447 76302 3.66 
2 h 12.491 82236 3.94 
3 h 12.278 79321 3.80 
6 h 12.354 81061 3.89 
ATV(3.25 mg/250 gm)+ 
RTV (2.13 mg/250 gm)+Piperine (30 mg/kg)  
30 min 11.090 37372 1.79 
1 h 11.120 76466 3.68 
2 h 11.060 203218 9.77 
3 h 11.143 82691 3.98 
6 h 11.119 30619 1.47 
GOR (30 mg/kg)+ATV(3.25 mg/250 gm) 30 min 12.471 55452 2.66 
1 h 12.379 107991 5.18 
2 h 12.276 33120 1.58 
3 h 12.364 27757 1.33 
6 h 12.361 20209 0.97 
 
First selecting the conventional 6.5 mg dose, the groups to be 
compared are Saline+ATV(H), ATV(H)+Piperine and ATV(H)+GOR. 
In the control group, the initial conc. is 4.90 µg/ml at 0.5 h, minimum 
conc. is 1.52 µg/ml at 1 h and maximum conc. obtained is 6.15 µg/ml 
at 3 h. After 3 h, the conc. of the drug decreases and is 4.54 µg/ml at 
6 h. The treated group, ATV(H)+Piperine, the initial conc. is 4.76 
µg/ml at 0.5 h, it then rises to 9.16 µg/ml at 1 h. Then the conc. starts 
decreasing, 8.49 µg/ml at 2 h and 1.94 µg/ml at 3 h.  
Thus it is clear from the above data, that the maximum conc. of the 
drug is 9.16 µg/ml at 1 h with the Piperine treated group. The conc. 
as well as the time, i.e., Cmax and Tmax both is higher for the 
piperine group in comparison to the control group. Graph-1 clearly 
shows the two-fold increase in the plasma concentration of the drug. 
The second treated group, ATV(H)+GOR, the initial conc. of the drug 
is 7 µg/ml at 0.5 h, then at 1 h it decreases to 4.01 µg/ml, at the 2 h, 
it again increase to 5.02 µg/ml, then it decreases to 1.42 µg/ml at 3 h 
and finally to 0.88 µg/ml at 6 h. The maximum conc. for the GOR 
treated group is 7 µg/ml at 0.5 h. Thus this maximum conc. is more 
than the control group, which is 6.15 µg/ml at 3 h. It indicates that the 
GOR also enhanced the bioavailability of the drug and that too the 
tmax is achieved earlier than that of the piperine group. However, 
among the two, piperine has more bioavailability enhancement effect. 
Thus the ATV(H)+piperine, has two times more bioavailability as 
compared to all the other groups of the higher dose.  
In case of ATV (3.25 mg) dose as compared to control group, 
Saline+ATV (L), the initial conc. of drug is 3.20 µg/ml at 0.5 h, then it 
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decreases to 1.96 µg/ml and then increases to 4.36 µg/ml. This is the 
maximum concentration of this group at 3 h. After this, the conc. 
again starts declining and reaches to 3.68 µg/ml at 6 h. In piperine 
treated group, the initial conc. of the drug is 2.91 µg/ml at 0.5 h, then 
the conc. increases to 3.66 µg/ml in 1 h, then to 3.94 µg/ml in the 2 
h. At 3 h, the conc. drops to 3.80 µg/ml and then again rises to 3.89 
µg/ml at 6 h. The maximum conc. among the above groups is 4.36 
µg/ml, for the control group at 3 h. The concentration obtained with 
piperine group is below 4.36 µg/ml. Fig. 2, shows the maximum 
conc. among the two, however in the case of control group, the 
concentration shows a considerable decrease after 3 h, whereas it is 
maintained in case of piperine. In ATV(L)+GOR, the initial conc. of 
the drug is 2.66 µg/ml at 0.5 h, at 1 h it is maximum with 5.18 µg/ml. 
It then decreases to 1.58 µg/ml at 2 h, 1.33 µg/ml at 3 h and 0.97 
µg/ml at 6 h. On comparing it with the control and piperine group, 
the conc. 5.18 µg/ml is maximium and at 0.5 h. 
For ATV+RTV groups, the conventional higher and lower doses of 
ATV are taken with 2.13 mg dose of RTV. The study of this 
combination is done with piperine. In the control group, 
Saline+ATV(H)+RTV, the initial conc. at 0.5 h is 3.77 µg/ml, and then 
it rises to 10.48µg/ml at 1 h and further to 10.82 µg/ml at 2 h, which 
is the maximum conc. Then at 3 h, it starts decreasing and is 
6.37µg/ml and at 6 h it is 3.45 µg/ml. In piperine treated group, the 
initial concentration at 0.5 h is 1.67 µg/ml, at 1 h it reaches 1.59µg/ml, 
and then decreases to 1.24µg/ml at 2 h, which is the minimum conc. At 
6 h, it is maximum 5.77 µg/ml. The blood sample at 6 h was not 
withdrawn as the animal died. On comparing the above results, the 
maximum conc. is 10.82 µg/ml at 2 h from the control group. In this 
case, the results show that the piperine is not able to have enhanced 
the conc. of the drug, since the maximum conc. in the piperine treated 
group is 5.77 µg/ml, or it can also be possible that the piperine treated 
group would have given the higher conc. at the 6 h. 
In the group Saline+ATV(L)+RTV, the initial conc. is 7.14 µg/ml at 
0.5 h, then it decreases to 3.07 µg/ml at 1 h. At 2 h, the conc. 
Increases to 6.09 µg/ml, and then decreases again to 5.51µg/ml at 3 
h and further to 1.515 µg/ml at 6 h. The maximum conc. is 7.14 
µg/ml at 0.5 h and minimum is 1.515 µg/ml at 6 h. For 
ATV(L)+RTV+piperine, the initial conc. is 1.79 µg/ml, then it 
increases to 3.68 µg/ml at 2 h. At 3 h, the concentration is 9.77 
µg/ml, which is maximum. After this, it starts decreasing, 3.98 µg/ml 
at 3 h and 1.47 µg/ml at 6 h. Here, on comparing both the groups, 
the maximum concentration obtained is 9.77 µg/ml at 3 h for the 
piperine group. From fig. 1, it is clear that the ATV(H)+RTV at higher 
doses gives the maximum concentration at 10.82 µg/ml which 
clearly indicates that RTV inhibits the host enzymes that 
metabolizes ATV as a protease inhibitors. However, 
ATV(L)+RTV+piperine group shows the highest concentration 9.77 
µg/ml which indicates that a combination with the piperine has 
more advantage as compared to the conventional combination. The 
conventional dose of ATV(H) with piperine gave maximum conc. of 
9.16 µg/ml at 1 h and the group, ATV(L)+RTV+piperine gave the 
maximum concentration 9.77 µg/ml at 3 h. Therefore, it is rather 
safer to use ATV(H) with piperine to produce the effective plasma 
concentration rather than the ATV(L)+RTV+piperine group, as the 
patient would avoid the adverse effects caused due to RTV. 
CONCLUSION 
Ritonavir (RTV) is generally given along with atazanavir (ATV) 
during the HIV treatment not for its antiviral action, but for its 
inhibitory effect on the host enzyme that metabolizes ATV and other 
protease inhibitors. Piperine and other natural bioavailabily 
enhancers have also the great potential to inhibit these host 
enzymes. ATV-piperine combination, both in higher and lower doses 
indicated maximum plasma concentration of the drug in blood, 
comparable to ATV-RTV combination. Further more extensive 
bioavailability studies are needed on this combination to confirm 
their role and use in the treatment of HIV-AIDS.  
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